We are live on !
Find out more
KCM
Knoll Capital Management Portfolio holdings
AUM
$214M
Turnover
5.26%
1-Year Est. Return
62.74%
This Fund
S&P 500
This Quarter Est. Return
+2.82%
1 Year Est. Return
+62.74%
3 Year Est. Return
+258.24%
5 Year Est. Return
+582.22%
10 Year Est. Return
+8,737.07%
AUM
$214M
AUM Growth
+$34.1M
(+19%)
Cap. Flow
+$15.5M
Cap. Flow % of AUM
Cap. Flow %
7.23%
Top 10 Holdings %
Top 10 Hldgs %
62.01%
Holding
38
New
1
Increased
5
Reduced
–
Closed
1
Avg Time Held
2.4
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
2.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elicio Therapeutics
ELTX
|
+$5.83M |
| 2 |
Ocular Therapeutix
OCUL
|
+$4.99M |
| 3 |
Abivax
ABVX
|
+$3.96M |
| 4 |
Nuvation Bio
NUVB
|
+$489K |
| 5 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$356K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cardiol Therapeutics
CRDL
|
+$135K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.06% |
| 2 | Materials | 37.64% |
| 3 | Miscellaneous | 8.28% |
| 4 | Industrials | 3.17% |
| 5 | Consumer Staples | 0.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $35M | 16.33% |
2,352,520
+23,918
| +1% | +$356K |
2017 Q2
36 quarters
|
|
2
MeiraGTx Holdings
MGTX
$885M
| $16.9M | 7.88% |
1,250,000
| – | – |
2024 Q3
7 quarters
|
|
3
Sprott Physical Gold
PHYS
$14.3B
| $11.7M | 5.45% |
387,055
| – | – |
2026 Q1
1 quarter
|
|
4
Aldeyra Therapeutics
ALDX
$39.2M
| $11.7M | 5.44% |
5,475,516
| – | – |
2015 Q1
45 quarters
|
|
|
5
Ocular Therapeutix
OCUL
$1.43B
| $11.3M | 5.27% |
1,150,400
+550,000
| +92% | +$4.99M |
2023 Q1
13 quarters
|
|
6
Royal Gold
RGLD
$19.3B
| $10.5M | 4.91% |
52,750
| – | – |
2023 Q3
11 quarters
|
|
7
Entera Bio
ENTX
$508M
| $10.4M | 4.86% |
5,881,879
| – | – |
2018 Q2
32 quarters
|
|
|
8
Nuvation Bio
NUVB
$1.6B
| $9.08M | 4.24% |
1,598,591
+100,000
| +7% | +$489K |
2025 Q1
5 quarters
|
|
9
Agnico Eagle Mines
AEM
$88.1B
| $8.18M | 3.82% |
52,750
| – | – |
2023 Q3
11 quarters
|
|
|
SA
10
Seabridge Gold
SA
$2.63B
| $8.16M | 3.81% |
317,003
| – | – |
2020 Q3
23 quarters
|
|
11
Kinross Gold
KGC
$26.5B
| $7.56M | 3.53% |
320,000
| – | – |
2023 Q3
11 quarters
|
|
12
OR Royalties Inc
OR
$6.15B
| $7.12M | 3.32% |
225,000
| – | – |
2026 Q1
1 quarter
|
|
13
SSR Mining
SSRM
$5.79B
| $6.93M | 3.23% |
245,000
| – | – |
2025 Q4
2 quarters
|
|
14
Franco-Nevada
FNV
$44.1B
| $6.67M | 3.11% |
32,000
| – | – |
2024 Q1
9 quarters
|
|
15
Booz Allen Hamilton
BAH
$9.42B
| $5.69M | 2.66% |
13,000
| – | – |
2021 Q1
21 quarters
|
|
16
Centerra Gold
CGAU
$3.96B
| $5.69M | 2.66% |
359,000
| – | – |
2025 Q2
4 quarters
|
|
|
17
Elicio Therapeutics
ELTX
$51.5M
| $4.74M | 2.21% |
1,211,957
+581,042
| +92% | +$5.83M |
2025 Q1
5 quarters
|
|
|
18
Abivax
ABVX
$7.68B
| $4.66M | 2.18% |
+35,000
| New | +$3.96M |
2026 Q2
0 quarters
|
|
19
Pan American Silver
PAAS
$16.6B
| $4.48M | 2.09% |
100,035
| – | – |
2025 Q3
3 quarters
|
|
20
Sprott Physical Silver Trust
PSLV
$11B
| $4.19M | 1.96% |
222,160
| – | – |
2026 Q1
1 quarter
|
|
21
Triple Flag Precious Metals
TFPM
$5.95B
| $3.45M | 1.61% |
115,000
| – | – |
2025 Q3
3 quarters
|
|
22
Abeona Therapeutics
ABEO
$252M
| $3M | 1.4% |
485,515
| – | – |
2025 Q2
4 quarters
|
|
23
Gold Royalty Corp
GROY
$656M
| $2.76M | 1.29% |
1,000,000
| – | – |
2026 Q1
1 quarter
|
|
24
New Pacific Metals
NEWP
$1.06B
| $1.95M | 0.91% |
485,000
| – | – |
2023 Q3
11 quarters
|
|
25
iShares US Aerospace & Defense ETF
ITA
$11.7B
| $1.85M | 0.87% |
7,650
| – | – |
2023 Q4
10 quarters
|
|
Similar funds
SF
Knoll Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Knoll Capital Management held 38 positions worth $214M, up 19% from $180M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Knoll Capital Management deployed $15.5M of net new capital in Q2 2026, opening 1 new position and adding to 5 existing holdings. Its largest new stake was Abivax: 35,000 shares worth $4.66M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 37% a quarter earlier, followed by Materials and Miscellaneous.
On the sell side, the most notable exit was Cardiol Therapeutics, an estimated $135K sold.
- Knoll Capital Management's largest Q2 2026 buy was Abivax: 35,000 shares worth $4.66M.
- Knoll Capital Management added most to Elicio Therapeutics in Q2 2026, an estimated $5.83M increase.
- Knoll Capital Management fully exited Cardiol Therapeutics in Q2 2026, selling an estimated $135K.
- Knoll Capital Management's ten largest holdings make up 62% of its $214M portfolio in Q2 2026.
- Knoll Capital Management opened 1 new position and closed 1 in Q2 2026.
- Knoll Capital Management's portfolio value rose 19% quarter-over-quarter to $214M.
Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.